Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026)
Johnson & Johnson (JNJ) posted Interest Expenses of $272.0 million for Q1 2026, up 27.1% sequentially from $214.0 million in Q4 2025, and up 33.33% YoY from $204.0 million in Q1 2025.
Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Interest Expenses data on file, last reported at $272.0 million in Q1 2026.
- Quarterly Interest Expenses rose 33.33% year-over-year to $272.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 29.23% YoY) and the FY2025 annual result came in at $971.0 million, up 28.61% from the prior year.
- Interest Expenses rose to $272.0 million in Q1 2026 per JNJ's latest filing, from $214.0 million in the prior quarter.
- The five-year high for Interest Expenses was $308.0 million in Q2 2025, with the low at $10.0 million in Q2 2022.
- Average Interest Expenses over 5 years is $177.8 million, with a median of $193.0 million recorded in 2024.
- Year-over-year, Interest Expenses slumped 84.13% in 2022 and surged 2020.0% in 2023.
- Johnson & Johnson's Interest Expenses stood at $51.0 million in 2022, then surged by 196.08% to $151.0 million in 2023, then retreated by 9.27% to $137.0 million in 2024, then surged by 56.2% to $214.0 million in 2025, then climbed by 27.1% to $272.0 million in 2026.
- Business Quant data shows JNJ's Interest Expenses at $272.0 million in Q1 2026, $214.0 million in Q4 2025, and $245.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 272.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -393.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -343.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 272.00 Mn |
| Mar 29, 2026 | 272.00 Mn |
| Dec 28, 2025 | 214.00 Mn |
| Dec 28, 2025 | 214.00 Mn |
| Sep 28, 2025 | 245.00 Mn |
| Sep 28, 2025 | 245.00 Mn |
| Jun 29, 2025 | 308.00 Mn |
| Jun 29, 2025 | 308.00 Mn |
| Mar 30, 2025 | 204.00 Mn |
| Mar 30, 2025 | 204.00 Mn |
| Dec 29, 2024 | 137.00 Mn |
| Dec 29, 2024 | 137.00 Mn |
| Sep 29, 2024 | 193.00 Mn |
| Sep 29, 2024 | 193.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Mar 31, 2024 | 155.00 Mn |
| Mar 31, 2024 | 155.00 Mn |
| Dec 31, 2023 | 151.00 Mn |
| Dec 31, 2023 | 151.00 Mn |